Insider Cluster (2 insiders) ·Filed May 22, 2026

MRNA

Moderna, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago
Insider cluster: 2 insiders, $3.0M total
Actionable Insight • Neutral

Insider sales are trivial relative to market cap and likely driven by routine diversification or tax planning. Hoge's sale may be tied to a 10b5-1 plan given the single large block. No bearish signal — ignore for trading purposes.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
MRNA ▲ +271.09% at T+60d
NEUTRAL call ✓ call won +271.09% · α vs SPY +268.63% · entry $46.99 → $174.38
Entry anchored
May 22, 2026
via day open
T+1d
+1.04%
call +1.04% · α +1.03%
$47.48
settled 4mo ago
T+5d
-2.96%
call -2.96% · α -4.17%
$45.60
settled 4mo ago
T+20d
+29.81%
call +29.81% · α +32.08%
$61.00
settled 3mo ago
T+60d
+271.09%
call +271.09% · α +268.63%
$174.38
settled 6w ago

Price Chart

Loading chart...

Executive Summary

Two Moderna insiders sold a total of $3.02M in open-market sales over a 7-day window. Director Noubar Afeyan exercised and sold 9,263 shares for $434K, while President Stephen Hoge sold 53,300 shares for $2.58M. The total sales represent ~0.016% of Moderna's $18.8B market cap, a trivial amount that does not signal material insider concern.

Key Financial Metrics

Direction
selling
Total Value
$3.0M
Insiders
2

Key Facts

  • Two insiders sold a combined $3.02M in open-market sales over 7 days
  • President Stephen Hoge sold 53,300 shares at $48.40 for $2.58M on 2026-05-15
  • Director Noubar Afeyan sold 9,263 shares at $46.84 for $434K on 2026-05-21
  • Total sales represent ~0.016% of Moderna's $18.8B market cap
  • Afeyan's sale followed derivative exercises at $0 and $19.15 per share (non-cash acquisition)
  • No insider purchases were reported in the cluster

Financial Impact

Total insider sales of $3.02M, representing 0.016% of market cap

insider holdings

Risk Factors

  • Insider sales could increase if stock rallies further, but current level is immaterial
  • No insider buying to offset the selling pattern

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
30% bullish (30 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-MRNA-1779490839769
18 reports for MRNA
Performance horizon
80% Hit rate 4 of 5 directional calls best @ T+60▲ +14.15%Mar 5, 2026
Filters
Rows
Reports for MRNA — sortable, filterable
TypeNow
Sep 30, 2026
2d ago
ANALYST-DOWNGRADE
BEARISH ★ 4/10
—awaiting T+5——
Sep 3, 2026
29d ago
ANALYST-DOWNGRADE
BEARISH ★ 6/10
$148.87 $143.97▲ +3.29%▲ +2.14%$187.38 (−25.87%)
Aug 31, 2026
4w ago
Court Ruling
BEARISH ★ 6/10
$140.19 $140.33▼ −0.10%▼ −0.24%$187.38 (−33.66%)
Aug 25, 2026
5w ago
ANALYST-UPGRADE
MIXED ★ 1/10
$158.83 $154.27▼ −2.87%▼ −2.33%$187.38 (+17.98%)
Aug 19, 2026
6w ago
ANALYST-UPGRADE
MIXED ★ 1/10
$174.38 $149.66▼ −14.18%▼ −13.79%$187.38 (+7.45%)
Aug 5, 2026
8w ago
144
BEARISH ★ 6/10
$56.26 $63.67▼ −13.18%▼ −12.83%$187.38 (−233.09%)
Jul 31, 2026
9w ago
8-K
MIXED ★ 6/10
$54.82 $59.17▲ +7.94%▲ +4.42%$187.38 (+241.81%)
Jul 10, 2026
11w ago
3
NEUTRAL ★ 2/10
$67.01 $61.82▼ −7.75%▼ −6.96%$187.38 (+179.63%)
Jul 8, 2026
12w ago
8-K
NEUTRAL ★ 2/10
$73.80 $67.44▼ −8.62%▼ −9.48%$187.38 (+153.90%)
Jun 18, 2026
15w ago
144
NEUTRAL ★ 2/10
$63.96 $59.75▼ −6.58%▼ −4.92%$187.38 (+192.96%)
Showing 10 of 18

US Market Status

Market Open — Closes in 1h 21m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published May 22, 2026